AUA 2017: The Effective Period of First Androgen-Deprivation Therapy Becomes a Prognostic Factor in Docetaxel Chemotherapy for Castration-Resistant Prostate Cancer Patients
201 patients were included in their cohort analysis with a median cancer specific survival of 21.5 months and a progression free survival of 13.5 months. 60.2% of patients achieved PSA nadir <0.2ng/ml. Multivariate analysis demonstrated that presence of visceral metastasis (HR 1.92, p=0.002), duration of ADT <16 months (HR 2.70, p<0.001), and time to start docetaxel >12 months (HR 1.64, p=0.004) were associated with worse progression free survival. Multivariate analysis also indicated that first ADT response <16 months, pretreatment PSA level ≥20 ng/ml, visceral metastasis, and ALP ≥284 were independent prognostic factors for CSS (HR=2.28, HR=1.69, HR=2.65, and HR=1.98, respectively).
This data indeed demonstrates that duration of 1st ADT is useful in predicting treatment response for castrate resistant prostate cancer patients treated with first line docetaxel therapy. Future studies are needed to corroborate this data.
Presented by: Keisuke Shigeta, MD
Authors: Keisuke Shigeta, Takeo Kosaka, Ryuichi MIzuno, Toshiaki Shinojima, Eiji KIkuchi, Akira MIyajima, Tokyo, Japan, Hitoshi Tanoguchi, Kanagawa, Japan, Shintaro Hasegawa, Utsunomiya, Japan, and Mototsugu Oya
Institution: Keio University School of Medicine, Tokyo, Japan
Written By: David B. Cahn, DO, MBS, Fox Chase Cancer Center, Philadelphia, PA
Twitter: @dbcahn
at the 2017 AUA Annual Meeting - May 12 - 16, 2017 – Boston, Massachusetts, USA